Abstract This report presents a case that was successfully treated for acquired factor VIII inhibitor after extensive visceral surgery. A 71-year-old male who underwent surgery for bile duct cancer had active bleeding in the abdominal drainage tube on postoperative day (POD) 5, and prolonged activated partial thromboplastin time (aPTT) was detected (83.1 s) on POD 7. An extensive coagulation work-up revealed factor VIII deficiency (1 %), and a diagnosis of an acquired factor VIII deficiency was established when a factor VIII inhibitor of 8 Bethesda units was demonstrated. The patient was treated with activated prothrombin complex concentrate (aPCCs) and bloody discharge was stopped within 3 days. Inhibitor elimination was started using prednisolone on POD 20; rituximab, was administered on POD 74 and 81. Factor VIII inhibitor had disappeared by POD 124, and factor VIII (72 %) and aPTT recovered to 45.9 s. This case report demonstrated the efficacy of aPCCs and rituximab in the treatment of acquired hemophilia associated with visceral surgery.
Introduction
Acquired hemophilia A (AHA) is a serious hemorrhagic disorder due to the formation of autoantibodies against coagulation factor VIII [1, 2] . However, the incidence of this rare disease is approximately 1.5 cases/million/year and little is known about its mechanism.
Many cases develop in association with malignancy, autoimmune disease or surgery, and are somehow associated with the elderly [1] [2] [3] . Unusual postoperative bleeding and an unexplained isolated prolonged activated partial thromboplastin time (aPTT) suggest the diagnosis of acquired hemophilia A, and a prompt investigation of such patients is therefore considered to be important. Fatal bleeding like this disease should be controlled during perioperative period. Some bypassing agents, such as recombinant activated FVII (rFVIIa) or activated prothrombin complex concentrate (aPCCs) [4] [5] [6] , are the first choice. In addition, subsequent immunosuppressive therapy is necessary for autoantibody eradication. Corticosteroids or combination therapy with cyclophosphamide has been recommended as the initial treatment; however, postoperative infectious disease and delayed wound healing are difficult complications [7] . Rituximab, a monoclonal chimeric antibody to the CD 20 antigen, has been shown to be effective for factor VIII inhibitor autoantibody eradication [7] [8] [9] .
This report presents a case of successful treatment of acquired factor VIII inhibitor using a bypassing agent and corticosteroids with rituximab, after extensive visceral surgery.
Case report
A 71-year-old male presented with jaundice and skin itching without a history of hemophilia or previous bleeding symptom. Computed tomography (CT) and nuclear magnetic resonance imaging (MRI) revealed that the dilated common bile duct was obstructed at the pancreatic portion by a tumor (Fig. 1) . Endoscopic retrograde biliary drainage was performed, and the laboratory data normalized. Acute obstructive cholangitis occurred 7 days before surgery due to trouble with the drainage tube. The primary drainage tube was removed and an endoscopic nasal biliary drainage tube was inserted to treat the cholangitis for better drainage. He recovered from the septic state but prolonged activated partial thromboplastin time (aPTT: 54.3 s) remained, thus indicating acquired hemophilia (Fig. 2) . His past medical history revealed hypertension, angina pectoris, moyamoya disease, diabetes mellitus, and pyothorax. These diseases were well controlled and he was physically active. Therefore, radical pancreaticoduodenectomy was performed for bile duct cancer. The perioperative blood loss was 330 ml. Doripenem (0.25 mg twice a day) and micafungin (50 mg/day) were administered for preventive treatment. Active bloody discharge from the abdominal drainage tube that was placed around intestinal anastomosis was found on postoperative day (POD) 5. The amylase level of the drain discharge was 16 IU/l and bacterial culture revealed a small amount of candida. Prolonged aPTT was getting worse (83.1 s on POD 7), and erythrocyte concentrate and flesh frozen plasma were transfused for progressive anemia (hemoglobin 6.2 mg/dl). CT could not detect any bleeding or pseudoaneurysm. Leakage of the gastrojejunostomy was detected on POD 10, and the bloody discharge continued. On POD 14, aPTT has reached 126 s and we consulted hematology staff (Fig. 2) . A detailed coagulation work-up revealed factor VIII deficiency (1 %), and diagnosis of an acquired factor VIII deficiency was established when a factor VIII inhibitor level of 8 Bethesda units was identified ( Table 1 ). The patient was treated with 50 units/kg twice daily of activated prothrombin complex concentrate [Factor VIII bypassing activity (FEIBA), Vienna, Austria], and the bloody discharge was stopped within 3 days. Inhibitor elimination was started using prednisolone (PSL 1 mg/kg/ day) on POD 20. No active bleeding was observed; however, an enterocutaneous fistula had developed at the gastrojejunostomy. PSL was tapered to 0.5 mg/kg/day on POD 30 to accelerate wound healing. However, aPTT was still prolonged and a subcutaneous and intramuscular hematoma that produced severe continuous pain developed on POD 37. FEIBA was administered at the same dose for 3 days, and the hematomas disappeared eventually (Fig. 3) . The central vein catheter was infected on POD 50 and removed immediately, but aPTT elongation was exacerbated by this event. Rituximab (375 mg/m 2 ), and a monoclonal chimeric antibody to the CD 20 antigen was administered on POD 74 as factor VIII inhibitor elimination therapy. Another rituximab was added on POD 81; PSL was reduced by half for a week on POD 86, and finally stopped on POD 120. Factor VIII inhibitor disappeared on POD 124, and factor VIII (72 %) and aPTT (45.9 s) recovered to a normal level (Table 1; Fig. 2 ). The enterocutaneous fistula finally closed on POD 137 and oral intake was started, and the patient's general condition was improving. He was thereafter transferred to a local hospital near his home on POD 187.
Discussion
The mechanism of acquired hemophilia is sometimes multifocal and remains uncertain. Production of the inhibitor autoantibody may be associated with systemic autoimmune disease such as RA and SLE but the condition may also develop due to a drug, malignancy, pregnancy or an operation [1] [2] [3] . Preoperative cholangitis and antibiotics may have been an initial trigger in the current case and invasive surgery for cancer might be another. Kreuter [10] reported a case of acquired hemophilia in a patient with gram-negative urosepsis and bladder cancer, and therefore infectious disease might produce acquired inhibitor antibody. It is very important to make an immediate diagnosis and to start appropriate treatment as soon as possible, but postoperative conditions are often complicated. It might be difficult to discriminate between this disease and other coagulopathy such as disseminated intravascular coagulation [11] . Three important clinical findings for diagnosis are significantly prolonged aPTTs, decreasing factor VIII activity, and the factor VIII autoantibody which is the proof of the presence of the inhibitor by the Bethesda method. No surgery should be performed if the clinical diagnosis of AHA is confirmed [8] . Surgery can be performed safely if the inhibitor autoantibody is appropriately removed [9] . The diagnosis of hemophilia was confirmed after postoperative bleeding in the current case, but hematological screening should have been initiated at the time point of the initial increase in the aPTT, and this kind of delay is often life threatening. Primary hemostasis must be the first priority. An extremely high titer inhibitor antibody does not respond to factor VIII replacement therapy, thus activated prothrombin complex concentrates or recombinant activated FVII has to be used for bypassing therapy [4] [5] [6] . Approximately, 80 % of postoperative bleeding caused by inhibitor antibody was controllable with aPCCs or rFVIIa, thus suggesting that individual patients might show different responses to therapy. A bleeding episode that indicates a poor response to bypassing therapy requires the switch to another agent; aPCCs were administered first in the current case, because that agent was immediately available.
Serious adverse effects associated with these treatments include DVT, myocardial infarction, and cerebral infarction due to clot formation, but the frequency of such adverse effects is in fact quite low. Fortunately, the current patient had no complications, such as angina and cerebral infarction. Therefore, primary hemostasis was successfully achieved. Autoantibody removal is then necessary to restore normal hemostatic conditions. Immunosuppressive therapy should continue until remission is achieved. Corticosteroids (1 mg/kg/day), which have been used for treatment of [7] , thus combination therapy is recommended as first choice. An antiCD20 antibody (rituximab) that selectively decreases B cell activity is also effective for the treatment of the autoimmune diseases such as ITP or AIHA that caused by an autoantibody. Therefore, it is used as combination therapy with steroids or even in as a monotherapy [7] [8] [9] . The remission rate is high (77 %), and it is listed as a recommendation because the antibody must be depleted until the patient achieves complete remission. The optimal treatment cannot be established without a randomized control trial. Infectious diseases are the most serious and frequent complication [5] . The effect of these immunosuppressive drugs on postoperative wound healing is more complicated and unclear. Steroids with rituximab successfully reduced the antibodies in the current case. The enterofistula was eventually closed, but it took a long time to treat the liver abscess. Rituximab monotherapy could be one of the choices in the case of surgery-associated acquired hemophilia [12] . However, it is not covered by insurance in Japan, so the patient was initially treated only with steroids. It took approximately one and a half months to the approval of the Institutional Review Board, which was another delay of treatment. There are few such throughout the world, thus it would be difficult to conduct a RCT. This case report could show the usefulness of aPCCs and rituximab in the treatment of acquired hemophilia associated with visceral surgery.
